Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Phathom Pharmaceuticals (PHAT – Research Report), ACELYRIN, INC. (SLRN – Research Report) and Moderna (MRNA – Research Report).
Phathom Pharmaceuticals (PHAT)
Goldman Sachs analyst Paul Choi maintained a Hold rating on Phathom Pharmaceuticals today and set a price target of $10.00. The company’s shares closed last Thursday at $10.32.
According to TipRanks.com, Choi is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Phathom Pharmaceuticals with a $22.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PHAT:
- Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- Phathom Pharmaceuticals initiated with a Buy at Stifel
- Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Phathom Pharmaceuticals launches direct-to-consumer campaign
- Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
